Corona Remedies Lists At 38% Premium on NSE After Strong IPO Subscription

Corona Remedies made a strong entry into the secondary market on December 11, 2025, after its initial public offering (IPO) witnessed robust demand. The company’s shares listed at ₹1,470 on the National Stock Exchange (NSE), reflecting a premium of 38.42% over the issue price.

On the Bombay Stock Exchange (BSE), the stock opened at ₹1,452, a 36.72% premium. The ₹655.37-crore IPO was subscribed 137.04 times during its offer period from December 8-10.

Market Debut

Shares of Corona Remedies opened at ₹1,470 per share on NSE, significantly above the upper end of the IPO price band of ₹1,062. On BSE, the listing price stood at ₹1,452 per share. The listing premium of 38.42% on NSE and 36.72% on BSE indicates strong investor interest.

Post listing, the company’s market capitalisation reached ₹8,880.44 crore. The IPO comprised an offer for sale (OFS) of 61.71 lakh shares by promoters and existing shareholders.

Background of the IPO

The ₹655.37-crore IPO of Corona Remedies was entirely an OFS, meaning the company will not receive any proceeds from the issue. Selling shareholders included Sepia Investments, Anchor Partners and Sage Investment Trust.

The IPO price band was set at ₹1,008-₹1,062 per share. JM Financial, IIFL Capital and Kotak Capital acted as book-running lead managers, while Bigshare Services was the registrar.

Financial and Operational Highlights

Corona Remedies is an India-focused branded pharmaceutical formulations company. It operates across therapeutic areas such as women’s healthcare, cardio-diabeto, pain management and urology.

According to CRISIL Intelligence, the company ranked as the second fastest-growing player among the top 30 firms in the Indian Pharmaceutical Market between MAT June 2022 and MAT June 2025. During this period, its domestic sales grew at a CAGR of 16.77%, outpacing the industry growth rate of 9.21%.

Market Reaction and Additional Details

The strong listing followed an exceptional subscription of 137.04 times in the primary market. Investor confidence was driven by the company’s consistent growth and presence in high-demand therapeutic segments.

Since the IPO was an OFS, the proceeds will go to selling shareholders rather than the company. The robust debut positions Corona Remedies among notable pharmaceutical listings in recent years.

Read More: Corona Remedies IPO Allotment Status.

Conclusion

Corona Remedies’ listing at a premium of over 38% underscores strong investor appetite for pharmaceutical stocks. The company’s market capitalisation of ₹8,880.44 crore reflects its growing stature in the domestic market.

With a subscription level of 137.04 times, the IPO attracted significant interest from institutional and retail investors. The debut reinforces the trend of healthcare-focused companies gaining traction in Indian equity markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.